We Offer Worldwide Shipping
Login Wishlist

Murrayanine

$1,152

  • Brand : BIOFRON

  • Catalogue Number : BN-O1595

  • Specification : 98%(HPLC)

  • CAS number : 723-97-7

  • Formula : C14H11NO2

  • Molecular Weight : 225.247

  • PUBCHEM ID : 96942

  • Volume : 5mg

Available on backorder

Quantity
Checkout Bulk Order?

Catalogue Number

BN-O1595

Analysis Method

HPLC,NMR,MS

Specification

98%(HPLC)

Storage

2-8°C

Molecular Weight

225.247

Appearance

Powder

Botanical Source

Structure Type

Alkaloids

Category

Standards;Natural Pytochemical;API

SMILES

COC1=CC(=CC2=C1NC3=CC=CC=C32)C=O

Synonyms

murrayanine/1-methoxy-carbazole-3-carbaldehyde/3-formyl-1-methoxy-9H-carbazole/9H-Carbazole-3-carboxaldehyde,1-methoxy/1-methoxy-9H-carbazole-3-carboxaldehyde/1-methoxy-3-formyl-9H-carbazole

IUPAC Name

1-methoxy-9H-carbazole-3-carbaldehyde

Density

1.312g/cm3

Solubility

Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc.

Flash Point

235.9ºC

Boiling Point

466.4ºC at 760 mmHg

Melting Point

InChl

InChI=1S/C14H11NO2/c1-17-13-7-9(8-16)6-11-10-4-2-3-5-12(10)15-14(11)13/h2-8,15H,1H3

InChl Key

FWNZQNAJETXQPP-UHFFFAOYSA-N

WGK Germany

RID/ADR

HS Code Reference

2933990000

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:723-97-7) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

No Technical Documents Available For This Product.

PMID

23234241

Abstract

Background
Tuberculosis (TB) and HIV co-infection remains a major public health problem. In spite of different initiatives implemented to tackle the disease, many countries have not reached TB control targets. One of the major attributing reasons for this failure is infection with HIV. This study aims to determine the effect of HIV infection on the survival of TB patients.

Findings
A retrospective cohort study was employed to compare the survival between HIV positive and HIV negative TB patients (370 each) during an eight month directly observed treatment short-course (DOTS) period. TB patient’s HIV status was considered as an exposure and follow up time until death was taken as an outcome. All patients with TB treatment outcomes other than death were censored, and death was considered as failure. Cox proportional hazard regression model was used to determine the hazard ratio (HR) of death for each main baseline predictor. TB/HIV co-infected patients were more likely to die; adjusted Hazard Rate (AHR) =1.6, 95%CI (1.01, 2.6) during the DOTS period. This risk was statistically higher among HIV patients during the continuation phase (p=0.0003), as a result HIV positive TB patients had shorter survival (Log rank test= 6.90, df= 2, p= 0.008). The adjusted survival probability was lower in HIV positive TB patients (< 15%) than HIV negative TB patients (> 85%) at the end of the DOTS period (8th month).

Conclusion
TB treatment survival was substantially lower in HIV infected TB patients, especially during the continuation phase. Targeted and comprehensive management of TB/HIV with a strict follow up should be considered through the entire TB treatment period.

KEYWORDS

TB treatment, Survival, TB patients, HIV positive, Hawassa, Health center

Title

Tuberculosis treatment survival of HIV positive TB patients on directly observed treatment short-course in Southern Ethiopia: A retrospective cohort study

Author

Debebe Shawenocorresponding author1 and Alemayehu Worku2

Publish date

2012;


Description :

Empty ...